‹ All Industries
Official DoP / DGCIS / NPPA / CDSCO Data
💊 India Pharmaceuticals Sector — Production, Trade & Policy Intelligence
National Pharma Turnover (2025-26 Est.)
₹5,20,000 Cr
▲ +154.1% vs 2015-16 (₹2.05L Cr)
Pharma Export Receipts (2024-25)
$30.47 Bn
▲ ₹2,59,658 Cr (+144.3% Growth)
Annual Trade Surplus (2024-25)
₹1,98,158 Cr
▲ Net Exporter (Surplus 4.2x Imports)
Active USFDA Facilities (2025-26)
752 Sites
▲ 520 Audit-Cleared (Global #1 ex-US)
📊 Executive Overview
🚢 Export & Import Dynamics
📈 Pricing & NPPA Regulation
🏭 Manufacturing & State Footprint
🏛️ Government PLI & Bulk Drug Parks
📋 Consolidated Master Repository
National Pharma Turnover & Export Growth Trajectory (2015-16 to 2025-26)
11-Year trajectory tracking overall industry turnover alongside export earnings (₹ Crore)
National Pharma Turnover
Pharma Export Receipts
₹5.20 Lakh Cr
Projected FY26 National Turnover, making India the "Pharmacy of the World".
$30.47 Billion
Export earnings in FY25, supplying generic medicines and vaccines to 200+ nations.
$15.28 Billion
Active Pharmaceutical Ingredient (API) & bulk drug domestic market valuation.
Global Outflow
Exports (FY25)
Export Value (INR)₹2,59,658 Cr
Export Value (USD)$30.47 Bn
10-Year Expansion▲ +144.3%
Imports
Imports (FY25)
Import Value (INR)₹61,500 Cr
Import Share of Turnover13.0%
GrowthManaged Plateau
Net Trade
Trade Surplus
2024-25 Surplus₹1,98,158 Cr
2015-16 Surplus₹74,076 Cr
Surplus Expansion▲ +167.5%
10-Year Trade Balance: Pharma Exports vs. Imports (₹ Crore)
Demonstrating consistent foreign exchange net surplus generation (Source: DGCIS)
Pharmaceuticals Export & Import Ledger
Official values in ₹ Crore & $ Billion
| Year | Export Value (₹ Cr) | Export Value ($ Bn) | Import Value (₹ Cr) | Net Trade Surplus (₹ Cr) | Export Growth YoY |
|---|
Wholesale Price Index (WPI) for Pharmaceuticals
Base 2011-12=100 tracking controlled inflation in medicine prices
NPPA Annual WPI-Linked Price Adjustments (%)
National Pharmaceutical Pricing Authority statutory price change notifications
CDSCO Market Approvals: New Drugs & FDCs (2015–2023)
Regulatory approvals for single molecular entities vs. Fixed-Dose Combinations (FDCs)
| Category | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|
| New Single Drugs | 20 | 33 | 32 | 27 | 26 | 27 | 25 | 30 | 27 |
| Fixed-Dose Combinations (FDCs) | — | — | — | — | 23 | 45 | 47 | 59 | 53 |
| Total Market Approvals | 20 | 33 | 32 | 27 | 49 | 72 | 72 | 89 | 80 |
Top Pharma Manufacturing Hubs by State
Distribution of 8,532 registered pharmaceutical units across India
USFDA Registered Facilities Trajectory
Total registered sites vs. audit-cleared manufacturing plants in India
State-Wise Registered Pharmaceutical Units (MoD / DoP)
Complete national industrial concentration
| State / Union Territory | No. of Pharma Units | Share of National Total (%) | Industrial Classification |
|---|
Mega Park
Gujarat Bulk Drug Park
Project Area2,015.0 Acres
Total Project Cost₹2,507.0 Cr
Central Funds Disbursed₹600 Cr (300+300)
Southern Hub
Andhra Pradesh Park
Project Area2,001.8 Acres
Total Project Cost₹1,876.7 Cr
Central Funds Disbursed₹225 Cr
Himalayan Hub
Himachal Pradesh Park
Project Area1,405.0 Acres
Total Project Cost₹1,923.0 Cr
Central Funds Disbursed₹225 Cr
PLI Scheme Across Strategic Sectors: Target Eligibility & Incentives
Production-Linked Incentives for Bulk Drugs, Key Starting Materials (KSMs) & Finished Formulations
| Target Sector | Minimum Investment (Per Project) | Government Incentive Rate | Target Product / Baseline Metric |
|---|---|---|---|
| Pharmaceuticals (Category 1 Drugs) | ₹500 Crore | 10% | Incremental sales over FY 2019–20 |
| Bulk Drugs & APIs (Chemical & Fermentation) | ₹50 Cr (₹400 Cr for Fermentation APIs) | 10% – 20% | Incremental sales of notified 41 bulk drugs |
| Medical Devices | ₹60 Crore | 5% | Incremental sales over FY 2019–20 |
| Large-Scale Electronics | ₹1,000 Crore | 4% – 6% | Incremental sales over FY 2019–20 |
| Automobiles & EV Components | ₹2,000 Cr (₹250 Cr for components) | 8% – 18% | Incremental sales over FY 2021–22 |
Interactive Pharma Macro Benchmarking
Compare any two indicators side-by-side across 2015-16 to 2024-25
Indicator 1
VS
Indicator 2
Consolidated Pharmaceuticals Sector Repository
Multi-dimension records across Production, Trade, Domestic Sales, WPI, FDI, and Infrastructure
Search Indicator
Category Filter
| Category | Metric / Indicator | Unit | Baseline (FY16) | FY21 | Latest Value (FY25/26) | Strategic Takeaway |
|---|